Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and PD of JNJ-54175446 in Healthy Men
NCT02515955Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2015
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of JNJ-54175446 in major depressive disorder (MDD) (8 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants with Adverse Events, Maximum Observed Plasma Concentration and 7 more. Started Aug 2015; status: completed.
02
Drugs
JNJ-54175446
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02515955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02515955.